Cargando…
Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials
BACKGROUND: Diabetes is common in patients with rheumatoid arthritis (RA). Interleukin (IL)-6 is implicated in both the pathogenesis of RA and in glucose homeostasis; this post hoc analysis investigated the effects of IL-6 receptor vs. tumour necrosis factor inhibition on glycosylated haemoglobin (H...
Autores principales: | Genovese, Mark C., Burmester, Gerd R., Hagino, Owen, Thangavelu, Karthinathan, Iglesias-Rodriguez, Melitza, John, Gregory St, González-Gay, Miguel A., Mandrup-Poulsen, Thomas, Fleischmann, Roy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488252/ https://www.ncbi.nlm.nih.gov/pubmed/32907617 http://dx.doi.org/10.1186/s13075-020-02229-5 |
Ejemplares similares
-
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
por: Burmester, Gerd R, et al.
Publicado: (2019) -
Glycaemia and critical care outcomes
por: Cecconi, M, et al.
Publicado: (2014) -
Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis
por: Boyapati, Anita, et al.
Publicado: (2020) -
Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade: Evidence of Improved Immune Regulation
por: Ablamunits, Vitaly, et al.
Publicado: (2012) -
Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study
por: Freedman, Mark S, et al.
Publicado: (2018)